Sanofi, TB Alliance Form Research Collaboration To Search For New Treatment Compounds

French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance “to accelerate the discovery and development of novel compounds against tuberculosis,” RTTNews reports (9/20). “According to company material, the projects will explore a compound which researchers believe has potential to treat all forms of tuberculosis, investigate another class of natural derivatives that has shown ‘impressive’ activity against tuberculosis bacteria, and identify future candidates for development among chemical compounds in Sanofi’s collection,” the Center for Global Health Policy’s “Science Speaks” blog writes (Barton, 9/20). RTTNews notes, “Sanofi, which discovered rifampicin in the early 1960s, markets several anti-tuberculosis drugs” (9/20).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.